Drug Development Archives | 第 2 页，共 19 页 | Certara

Blog

Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations

Learn how regulatory expectations in clinical pharmacology are evolving and how to build a strategy…

Certara2026 年 3 月 24 日

Guide

Pediatric Drug Development and Pharmacometrics: Key Questions Sponsors Must Answer

Download Certara’s expert guide on pharmacometrics and pediatric drug development. Learn how modeling, MIDD, and…

Certara2026 年 3 月 19 日

Blog Knowledge Base

What is GLP (Good Laboratory Practice)?

Read this blog to understand GLP (Good Laboratory Practice) and associated QA audits, and proper…

Certara2026 年 3 月 18 日

Conference

Discovery & Development Europe 2026

Certara2026 年 3 月 13 日

Announcement

Certara Welcomes Arjun Bedi to its Board of Directors 

Certara has appointed Arjun Bedi to its Board of Directors. His life sciences expertise will…

Certara2026 年 3 月 12 日

Blog

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

Explore how model-informed drug development and AI are advancing pharmacoequity and shaping the future of…

Certara2026 年 3 月 11 日

Announcement

Certara Announces 2026 Certainty Event

CERTAINTY 2026: Explore AI-driven drug development and technological innovation at the leading biosimulation event for…

Certara2026 年 3 月 9 日

Webinar

Building Trust in Data – Transparency, Traceability, and the Human Element

Danielle Pillsbury2026 年 3 月 5 日

Webinar

Virtual Control Groups, Actually: What SEND Makes Possible (and What It Doesn’t)

Certara2026 年 3 月 4 日

Publication

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

This study used model-based meta-analysis (MBMA) to assess how well objective response rate (ORR) predicts…

Danielle Pillsbury2026 年 3 月 4 日

© 2026 Certara. 保留所有权力。 | 法律 | 隐私政策

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software